Staff Photo, Daye Peak Packaging Central Control Operator Ke Yaozhen Do What He Should Do
Release time:
2022-11-23
"does not compete with others for the short and long of interests, only with others for the length of character, and does what you should do well. " This is a portrayal of Ke Yaozhen, the central control operator of Daye Peak Packaging System, in her daily work, and also her excellent character in this ordinary position.
She was born in 1987 and entered Daye Peak in 2012 . She has been engaged in packaging cement delivery and is the youngest delivery worker in Daye Peak. At first, she gave me the impression that a very hot-tempered little girl was enthusiastic, loud-voiced, decisive and vigorous, never sloppy, and looked like a newborn calf who was not afraid of tigers. The central control operator of
packaging is the central link of the entire delivery system, undertaking cement warehouse dumping and ash release, bag and bulk cement delivery, communication and communication between on-site loading vehicle drivers and delivery system personnel, and arrangement of opening and stopping. In this complex relationship environment, there are personnel with various personalities, and the quality of personnel is uneven. Because of different positions, inconsistent views, and different nature of work, there will be a lot of communication and interaction with them. Not easy.
When dealing with the problems at the scene, Ke Yaozhen was very capable and vigorous, with strong principles and no room for half a grain of sand in his eyes. Whether it is the vehicle driver on the scene or the colleagues on the scene, as long as they violate the management regulations or the work is not carried out properly, they will hear the familiar loud voice patiently explaining and correcting there. However, she can understand and tolerate the relationship between colleagues, regardless of personal gains and losses, and knows how to endure concessions. Bowing your head "to recognize the unintelligent " seems to be a kind of cowardice, but in fact it is a kind of posture to deal with people and a necessary wisdom in life.
Ke Yaozhen is also very responsible in terms of work execution. Whether it is the health area divided by job responsibilities, or explaining her other work tasks, or some problems found on the scene by herself, regardless of the cold and hot winter, she can often be seen spontaneously dealing with things in a certain place. At this time, she, like a changed person, acted very low-key. When you give her a job assignment, you are there to seriously emphasize the implementation standards of the job, and she will joke to you, "You are a busy person, you go and do your job. Leave this matter to me. " Full confidence is revealed in your speech and behavior. When checking the completion of her work, I have to admire her execution and execution standards.
"Lu Yao knows horsepower, and you see people's hearts for a long time. " It is an employee like Ke Yaozhen who, with feelings for the company and a grateful heart, gives without complaint or regret in an ordinary job and does his best to shine his own light. The order of our on-site vehicles is well and orderly, the production site is clean and tidy, and it has been repeatedly affirmed by enterprise management personnel.
(Huang Bide)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31